The Lung Cancer Alliance (LCA) has launched a new screening initiative called the Framework for Lung Cancer Screening Excellence that includes a bill of rights for individuals at risk of the disease, along with guiding principles for lung cancer screening programs.
The goal of the initiative is to move screening into the clinical realm through the efforts of "thoughtful and responsible" leaders, said Laurie Ambrose, LCA's president and CEO, in a February 9 statement.
Lung cancer's 15% survival rate has barely budged in 40 years, but lung cancer screening -- if properly executed -- has the potential to save more lives than other cancer screening programs, according to LCA.
The national framework states that individuals have a right to know if they are at risk for lung cancer, and they should seek screening only at sites that follow certain guiding principles outlined in LCA's initiative.
Those principles include having a properly implemented screening program and a comprehensive continuum of care, with clinical specialists in pulmonary disease, thoracic surgery, radiology, and oncology, wrote Dr. William Mayfield, chief surgical officer for WellStar Health Systems, which developed the protocol included in the LCA framework.
The initiative also establishes a Screening Excellence Forum of leaders to develop a dynamic system to collect data and specimens incorporating advances in imaging and biomedicine as they are validated. The framework encourages research into biomarkers, precancerous conditions, and targeted therapies that can be enhanced by collecting biological samples during screening. The framework can be found at LCA's website.

















![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&fit=crop&h=112&q=70&w=112)

